AI-Guided Prediction Device for Cardiac Arrest

LW
JN
Overseen ByJulie Nichols Research Coordinator, RN
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: MetroHealth Medical Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

Sudden cardiac arrest is a major health problem, and most people don't survive. One big reason is that even if resuscitation is successful, people commonly have recurrent cardiac arrests (rearrest). Right now, it is not possible to accurately predict a rearrest or prevent it. The investigators have developed a machine learning device that uses the heart tracing (ECG) to predict when and why a rearrest occurs. The investigators plan to test if it will accurately and effectively help EMS providers predict rearrest and provide timely treatment to increase survival after cardiac arrest. To determine if this machine learning device will work in the real world, the investigators need to find out if there are barriers to using it, and whether EMS providers will think it is useful and will help them improve the care of patients who have a cardiac arrest. The investigators will first test the device in live simulated cardiac arrest scenarios to see if the providers can use it and if they find the device potentially valuable in taking care of patients. In a second study, the investigators will test how accurate the device is in predicting if a cardiac arrest will happen again in patients who have just been brought back to life after a cardiac arrest. EMS providers will attach the device, but it will only work in the background. EMS will take care of patients as they normally would, without using or knowing what the device says. To see if the device is accurate at predicting another cardiac arrest, the investigators will analyze the results offline, and compare what the device says to what actually happens to the patient. By comparing what the device predicts to what actually happens, the investigators can see how well it predicts another cardiac arrest and estimate how it might improve treatment of patients.

Are You a Good Fit for This Trial?

Inclusion Criteria

I am an EMS provider who is 18 years old or older.
I am 18 or older and have survived a cardiac arrest outside the hospital.

Exclusion Criteria

Providers who do not care for cardiac arrest patients
Prisoners
Patients with DNR/DNI orders
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Simulation Phase

Emergency Medical Service Providers participate in high fidelity cardiac arrest simulations to test the machine learning guided prediction device

1 day
1 visit (in-person)

Observational Phase

Patients who experience cardiac arrest are observed while a machine learning guided prediction device runs in the background

Up to 2 hours per patient

Follow-up

Participants are monitored for safety and effectiveness after the observational phase

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Machine learning-guided cardiac arrest prediction device

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Patients who experience cardiac arrest cared for by EMSExperimental Treatment1 Intervention
Group II: Emergency Medical Service ProvidersExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

MetroHealth Medical Center

Lead Sponsor

Trials
125
Recruited
22,600+

National Center for Advancing Translational Sciences (NCATS)

Collaborator

Trials
394
Recruited
404,000+